Levetiracetam market is anticipated to grow at a significant CAGR during the forecast period (2023-2029). Levetiracetam is a medication that is sold under the brand name Keppra among others and is used to treat epilepsy. This medicine is used for partial-onset, myoclonic, or tonic-clonic seizures. It is consumed by mouth as an immediate or extended-release formulation or by injecting directly into a vein. The major factor for the growth of the market is the rising prevalence of epilepsy.
According to the World Health Organization (WHO), in 2019, epilepsy is one of the most common neurological diseases globally with around 50 million people diagnosed with it. Additionally, almost 80% of people with epilepsy live in low and middle-income countries and up to 70% of people living with epilepsy could live seizure-free if properly diagnosed and treated. However, the risk of mortality is three times higher in people with epilepsy than in the general populace. Hence the rising prevalence of epilepsy is driving the demand for levetiracetam which in turn is boosting the market growth.
Some major key players in the market include Mylan NV, UCB Pharma Ltd., and Novartis International AG (Sandoz Inc.), among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in June 2018, Sandoz Canada announced the launch of Sandoz Levetiracetam 1000 mg to be used as adjunctive therapy to manage patients with epilepsy who are not satisfactorily controlled by conventional therapy.
To Request a Sample of our Report on Levetiracetam Market: https://www.omrglobal.com/request-sample/levetiracetam-market
Market Coverage
- The market number available for – 2022-2029
- Base year- 2022
- Forecast period- 2023-2029
- Segment Covered-
- By Form
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Mylan NV, UCB Pharma Ltd., and Novartis International AG (Sandoz Inc.), among others.
Levetiracetam Market Report by Segment
By Form
- Tablet
- Syrup
- Injection
By Application
- Myoclonic Treatment
- Tonic-clonic Seizures Treatment
A full Report of Levetiracetam Market is Available at: https://www.omrglobal.com/industry-reports/levetiracetam-market
Levetiracetam Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
